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Abstract
Background: Primaquine is currently the only medication used for radical cure of Plasmodium vivax infection.
Unfortunately, its use is not without risk. Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency have
an increased susceptibility to haemolysis when given primaquine. This potentially fatal clinical syndrome can be
avoided if patients are tested for G6PD deficiency and adequately informed before being treated.
Case presentation: A 35-year old male presented to our clinic on the Thai-Burmese border with a history and
clinical examination consistent with intravascular haemolysis. The patient had been prescribed primaquine and
chloroquine four days earlier for a P. vivax infection. The medication instructions had not been given in a language
understood by the patient and he had not been tested for G6PD deficiency. The patient was not only G6PD
deficient but misunderstood the instructions and took all his primaquine tablets together. With appropriate
treatment the patient recovered and was discharged home a week later.
Conclusions: Whilst primaquine remains the drug of choice to eradicate hypnozoites and control P. vivax
transmission, the risks associated with its use must be minimized during its deployment. In areas where P. vivax
exists, patients should be tested for G6PD deficiency and adequately informed before administration of primaquine.
Background
Plasmodium vivax contributes to a significant propor-
tion of malaria infections worldwide and it is the domi-
nant species of malaria in many areas outside Africa [1].
Between 70 to 390 million infections are estimated to
occur each year with about 80% of these infections
occurring in South and South East Asia [2]. Unlike Plas-
modium falciparum,t h eP. vivax parasite has a dormant
liver stage [3]. Hypnozoites reside in the liver for pro-
longed periods of time before rupturing into the blood
and causing a relapse of P. vivax infection. Once
P. vivax has been eliminated from the bloodstream, the
remaining hypnozoites must be eradicated from the
liver to prevent relapse of infection. This is known as
radical cure. Hypnozoites appear to be the dominant
source of new parasitaemia and consequently further
transmission of P. vivax malaria. Eradication of hypno-
zoites may, therefore, be an effective method for redu-
cing the disease burden of P. vivax. Primaquine, an
8-aminoquinoline, is currently the only medication used
for radical cure of P. vivax. It is recommended by the
World Health Organization (WHO) to prevent relapse
in patients infected with P. vivax malaria in areas of low
transmission[4]. Despite this ,d u et om a n yf a c t o r s ,o n l y
am i n o r i t yo fp a t i e n t sa c t u a l l yr e c e i v ep r i m a q u i n ef o r
P. vivax infection [5].
The use of primaquine is not without its risks.
Patients with the inherited sex-linked deficiency of glu-
cose-6-phosphate dehydrogenase (G6PD), have an
increased susceptibility to acute intravascular haemolysis
when treated with oxidant drugs such as primaquine
[6]. Exposed patients commonly present with severe
abdominal pain, nausea, vomiting and headache. High
fevers with rigors can also be seen. The urine becomes
almost black and output drops as renal failure ensues.
This severe clinical syndrome of intravascular haemoly-
sis, haemoglobinuria and acute renal failure is known as
black water fever.
This potentially fatal clinical syndrome can be avoided
if patients are tested for G6PD deficiency before the
administration of primaquine. The most reliable way to
detect G6PD deficiency is by DNA analysis, but a diag-
nosis of G6PD deficiency can also be made by a rapid
fluorescent spot test [7]. The International Committee
for Standardization in Haematology recommended this
test as the most acceptable method for screening [8].
If the patient is deficient, the blood spot will fail to
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and inexpensive and, therefore, suitable for use in the
field. It does however require a UV light source and,
therefore, electricity, which can limit its use in resource
poor settings. In response to this problem, other qualita-
tive screening tests have recently been developed which
do not require a UV light source, however they present
other disadvantages in terms of cost, time and feasibility
in the field [9], [10]. New rapid tests are being devel-
oped, which do not require special storage or perform-
ing conditions and couple malaria detection and G6PD
activity assessment. These could represent a great tool
for field analysis [11].
Case presentation
A 35-year-old male was carried to SMRU malaria clinic
o nt h eT h a i - B u r m e s eb o r d e r .H ew a sc o n f u s e d ,l o o k e d
unwell, had rigors and was too weak to stand. His tem-
perature was 37.4°C, he was tachypnoeic with a respira-
tory rate of 26/minute and had oxygen saturations of
83% on air. He had cold peripheries, a pulse rate of
93/min and a blood pressure of 80/65 mmHg.
His low oxygen saturations corrected with the admin-
istration of oxygen. Given the hypotension, tachycardia
and pyrexia, both intravenous fluids and empirical cef-
triaxone were begun.
Further assessment found pale conjunctiva and yellow
sclera. His abdomen was diffusely tender but the liver
and spleen were not palpable. His examination was
otherwise unremarkable.
His malaria smear was negative and he was normogly-
caemic (193 mg/dl). However his capillary blood haema-
tocrit (Hct) was only 18% and his urine sample was
almost black (Figure 1). His urea and creatinine were
elevated at 53.3 mg/dl and 2.1 mg/dl respectively. His
full blood count showed white blood cell 21.6 x10
3 /μL,
haemoglobin 6.9 g/dL and platelet count 136 × 10
3/μL.
It is possible that the leukocytosis could be a conse-
quence of the haemolytic crisis itself [12]. Despite cef-
triaxone therapy, the patient remained febrile with a
leucocytosis at day three of admission. Given his clinical
condition at this stage, gentamicin was added to his
treatment and antibiotics were continued for a total of
seven days. Acinetobacter baumannii was isolated from
the admission blood culture: by disc testing using cur-
rent CLSI criteria, the organism was sensitive to all
drugs tested: amikacin, ceftazidime, ciprofloxacin, genta-
micin, meropenem, and piperacillin-tazobactam. The
clinical significance of this culture result is uncertain
since the organism is usually responsible for infections
in hospitalized patients [13].
Following initial treatment the patient became coher-
ent enough to answer questions appropriately. He was a
Burmese construction worker working on the Thai-
Burmese border. Following a four-day history of fever,
he attended a local clinic where a malaria smear con-
firmed he had malaria. He received two types of tablets,
but was unsure of their names. The patient identified
the tablets, using examples of anti-malarial medications,
to be chloroquine and primaquine. As reportedly pre-
scribed, the patient took three chloroquine tablets a day
(10 mg/kg) and one primaquine tablet (15 mg base) a
d a yf o rt h ef i r s tt w od a y s .O nt h et h i r dd a yh et o o k
one-and-a-half chloroquine tablets (5 mg/kg) and one
more primaquine tablet (15 mg base). He did note a
change in colour of his urine on the third day but was
not alarmed by this. On day four he could not remem-
ber the instructions of what to do with the eleven
remaining primaquine tablets. The handwritten instruc-
tions were in Thai, which he was unable to read. His
colleague translated the label, telling him he must finish
all the tablets. Subsequently, the patient took the last
eleven primaquine tablets in one go (165 mg base).
Later that day the patient began to vomit and a severe
abdominal pain ensued associated with black urine.
Following this additional history, a second malaria
smear was performed, which still showed no evidence of
malaria. A rapid fluorescent spot test showed the patient
to be G6PD deficient even though after a massive hae-
molysis, a normal phenotype would be expected as older
red blood cells (RBCs) are destroyed and new ones, with
normal phenotype, are produced. A correct protocol to
avoid misinterpretation of the test after haemolysis,
which has not been applied here, would have been to
separate older RBCs and assess G6PD activity only on
them. Genotyping through the PCR-restriction fragment
length polymorphism (PCR-RFLP) method was later
applied to detect known G6PD mutations [14]. This
confirmed that the patient was hemizygote for the
Mahidol variant (Figure 2).
Figure 1 A sample of the patient’s urine at admission. The black
colour of the urine is due to the presence of haemoglobinuria.
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intravenous fluids, the patients condition improved, his
urine returned to normal and his Hct stabilized at 24%.
At this level of anaemia, the local guidelines advise no
further transfusion. The patient was discharged home
on a treatment dose of ferrous sulphate (200 mg tds)
and folic acid (5 mg od). A thorough explanation of the
cause of his life-threatening illness was given to the
patient in his own language and strict instructions, both
verbal and written, explaining which medicines he
should never take. Despite arranging follow-up to moni-
tor the patient’s renal function and anaemia, the patient
did not return as he moved from the area.
Conclusions
As G6PD deficiency confers an element of protection
against infection with malaria, the two pathologies often
exist side-by side in the same population [15,16]. In areas
where P. vivax exists, the prevalence of the enzyme defect
should be established, as it can be as high as 30% [17].
The rapid fluorescent spot test is a relatively inexpensive
and simple test to run. Therefore testing for G6PD defi-
ciency before administration of primaquine should be
mandatory in areas where the deficiency is found to be
common. Nonetheless the rapid test is qualitative and
can be considered reliable only to detect complete defi-
cient phenotypes. The interpretation of intermediate
fluorescent test is more difficult and the decision about
the treatment should follow the precautionary principle.
There are many different genotypes of G6PD defi-
ciency. Each genotype is associated with a different level
of enzyme deficiency and therefore susceptibility to hae-
molysis [18,19]. These different genotypes can only by
identified by DNA analysis, which is not routinely avail-
able. What’s more, within a given genotype there is a
wide range of enzyme deficiency and therefore DNA
analysis is still not entirely predictive of the haemolytic
risk. To reduce the risk of haemolysis, the WHO cur-
rently makes the following recommendations: In
patients with mild G6PD deficiency i.e. those patients
with a history of tolerability of primaquine, the WHO
suggests using an intermittent primaquine regimen of
0.75 mg base/kg once a week for eight weeks [4]. How-
ever, there is limited evidence to support this [20]. Pri-
maquine is contraindicated in patients with severe
glucose-6-phosphate dehydrogenase deficiency, there-
fore, in regions where prevalence of G6PD deficiency is
relatively high, G6PD testing is required before adminis-
tration of primaquine [4].
The exact prevalence of G6PD deficiency on the Thai-
Burmese border is not yet fully characterized. However,
t h ee n z y m ed e f e c ti sk n o w nt ob ec o m m o ni nt h i sa r e a
with G6PD Mahidol thought to be the most frequent
mutation [19,21]. Research done by Buchachart et al
suggests that administration of primaquine to patients
with the Mahidol variant is relatively safe, but further
research is needed [22]. Until these aspects of G6PD
deficiency are better understood and the characteriza-
tion of other deficient mutations in the local population
is established (including their spatial distribution and
the phenotypes associated with), in the absence of con-
firmed G6PD-normal status or evidence of previous
primaquine tolerability, primaquine should not be
administered.
The Thai Ministry of Public Health advocates using
chloroquine and primaquine in the treatment of
P. vivax, but gives no guidance on the use of G6PD test-
ing [23]. Along the Thai-Burmese border, limited testing
facilities for G6PD deficiency exist and primaquine is
still prescribed in some clinics without confirming that
the patient is G6PD normal. The consequence of such
practice is demonstrated by this case and serves to
remind that acute haemolysis is a real and potentially
fatal consequence when primaquine is administered to
patients with G6PD deficiency.
This case illustrates that low functional literacy can
have serious consequences for individual health. Along
the Thai-Burmese border, languages and dialects vary
greatly according to the latitude. There is not one
unique language spoken by all patients and medical staff
in this area, making communication challenging.
Furthermore there are high rates of illiteracy (<50%) in
this area [24].
There is a strong association between patient literacy
and adherence to malaria medication [25]. In order to
Figure 2 Electrophoresis gel confirming the patient to be
hemizygote for Mahidol variant of G6PD deficiency. From the
left side. Line 1: Molecular marker 100 bp; L2: Mahidol hemizygote;
L3 Patient sample; L4:G6PD normal; L5: G6PD normal/Mahidol
heterozygote; L6: molecular marker 25 bp.
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ment, the role of the healthcare provider should go
beyond the diagnosis and treatment of malaria and must
include interventions that aid patient adherence and
understanding [26]. The problem of illiteracy can be
overcome by simple methods even when the majority of
individuals are illiterate. It is essential that verbal
instructions be given to the patients, as written instruc-
tions may be of limited use. Even with verbal instruc-
tions, patients with low literacy skills take words literally
without interpreting them, so it is also imperative that a
translator is used to ensure the full understanding of the
patient [27]. A vital step in this process is to verify the
patient’s understanding of their illness and their medica-
tions by having them repeat back in their own language,
what they are to do and why [28]. Clear visual instruc-
tions to take home are also important to support verbal
communication. Studies have shown that pictorial aids
improve understanding, and adherence, particularly
when they are used together with oral instructions [29].
Visual aids are particularly useful for explaining when to
take medications, and the importance of completing the
therapy. At the very least, the patient should understand
how to take his medication and when to seek further
medical advice.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompany-
ing images. A copy of the written consent is available
for review by the Editor-in-Chief of this journal.
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